Form 4: Supernus Pharmaceuticals Executive Padmanabh P. Bhatt Reports Changes in Beneficial Ownership

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, reports transactions involving common stock and derivative securities, including the vesting and settlement of performance share units and restricted stock units.

Summary

• On February 21, 2025, Padmanabh P. Bhatt settled 1,650 performance share units, receiving common stock.
• 860 shares of common stock were withheld by Supernus Pharmaceuticals to cover tax obligations related to the vesting of these performance share units at a price of $39.15.
• Between February 22 and February 23, 2025, Bhatt acquired a total of 3,250 shares of common stock through the vesting of restricted stock units.
• Following these transactions, Bhatt directly owns 14,189 shares of Supernus Pharmaceuticals common stock.
• Bhatt also holds derivative securities, including 750 restricted stock units vesting on February 22, 2023, 3,750 restricted stock units vesting on February 22, 2025, and 2,500 restricted stock units vesting on February 23, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine transactions related to executive compensation. There are no explicit positive or negative implications for the company's performance.

Positives

• The vesting of performance share units and restricted stock units indicates that the executive is meeting performance objectives and is incentivized to continue doing so.

Negatives

• The withholding of shares to cover tax obligations reduces the net gain for the executive.

Future Outlook

The executive's holdings will continue to change as restricted stock units vest over time.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, restricted stock units, and performance-based awards.
• Vesting schedules for restricted stock units typically occur over several years to incentivize long-term commitment.
• Companies like Teva Pharmaceuticals, Eli Lilly, and AbbVie also use similar equity-based compensation strategies to align executive interests with shareholder value.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the value of existing shares as new shares are issued upon vesting of restricted stock units.

Key Dates

Keywords

Supernus Pharmaceuticals, Bhatt, beneficial ownership, Form 4, performance share units, restricted stock units, common stock, vesting, executive compensation